Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Accumulated Expenses: 2024-2025

  • ARS Pharmaceuticals' Other Accumulated Expenses was N/A to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year change of. This contributed to the annual value of $570,000 for FY2024, which is N/A change from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Other Accumulated Expenses stood at $3.1 million, which was up 440.88% from $570,000 recorded in Q4 2024.
  • In the past 5 years, ARS Pharmaceuticals' Other Accumulated Expenses ranged from a high of $3.1 million in Q3 2025 and a low of $570,000 during Q4 2024.
  • Over the past 2 years, ARS Pharmaceuticals' median Other Accumulated Expenses value was $1.8 million (recorded in 2024), while the average stood at $1.8 million.